Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-trace').style.display = (document.getElementById('cakeErr68004fd88d1c4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68004fd88d1c4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-code').style.display = (document.getElementById('cakeErr68004fd88d1c4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-context').style.display = (document.getElementById('cakeErr68004fd88d1c4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68004fd88d1c4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68004fd88d1c4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29051,
		&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677105,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29051,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29051,
	&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677105,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29051
$metaTitle = &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;
$metaDesc = &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br />This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br /><br />These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br /><br />The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br /><br />Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br /><br />In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br /><br />The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br /><br />As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-trace').style.display = (document.getElementById('cakeErr68004fd88d1c4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68004fd88d1c4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-code').style.display = (document.getElementById('cakeErr68004fd88d1c4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-context').style.display = (document.getElementById('cakeErr68004fd88d1c4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68004fd88d1c4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68004fd88d1c4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29051,
		&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677105,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29051,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29051,
	&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677105,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29051
$metaTitle = &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;
$metaDesc = &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br />This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br /><br />These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br /><br />The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br /><br />Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br /><br />In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br /><br />The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br /><br />As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-trace').style.display = (document.getElementById('cakeErr68004fd88d1c4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68004fd88d1c4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-code').style.display = (document.getElementById('cakeErr68004fd88d1c4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68004fd88d1c4-context').style.display = (document.getElementById('cakeErr68004fd88d1c4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68004fd88d1c4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68004fd88d1c4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29051,
		&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677105,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29051,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29051,
	&#039;title&#039; =&gt; &#039;Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;
&lt;br /&gt;
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;
&lt;br /&gt;
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;
&lt;br /&gt;
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;
&lt;br /&gt;
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;
&lt;br /&gt;
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677105,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29051
$metaTitle = &#039;LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee&#039;
$metaKeywords = &#039;Access to Medicines,Medicine Prices,diabetes,Insulin&#039;
$metaDesc = &#039;
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &amp;quot;pushed&amp;quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.&lt;br /&gt;&lt;br /&gt;These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. &lt;br /&gt;&lt;br /&gt;The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers&#039; reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.&lt;br /&gt;&lt;br /&gt;Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &amp;quot;I strongly believe that some newer and costly insulin are being &#039;pushed&#039; to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&amp;quot;&lt;br /&gt;&lt;br /&gt;In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation &#039;rapid and long acting&#039; (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.&lt;br /&gt;&lt;br /&gt;The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.&lt;br /&gt;&lt;br /&gt;As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br />This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br /><br />These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br /><br />The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br /><br />Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br /><br />In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br /><br />The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br /><br />As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 29051,
		'title' => 'Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India<br />
<br />
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br />
<br />
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br />
<br />
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br />
<br />
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br />
<br />
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br />
<br />
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br />
<br />
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
</div>',
		'credit_writer' => 'The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4677105,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 29051,
	'metaTitle' => 'LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee',
	'metaKeywords' => 'Access to Medicines,Medicine Prices,diabetes,Insulin',
	'metaDesc' => '
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...',
	'disp' => '<div align="justify">-The Times of India<br /><br />This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br /><br />These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br /><br />The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br /><br />Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br /><br />In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br /><br />The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br /><br />As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 29051,
	'title' => 'Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India<br />
<br />
This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br />
<br />
These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br />
<br />
The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br />
<br />
Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br />
<br />
In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br />
<br />
The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br />
<br />
As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.
</div>',
	'credit_writer' => 'The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'pharma-firms-push-costly-insulin-at-patients-expense-rupali-mukherjee-4677105',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4677105,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 29051
$metaTitle = 'LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee'
$metaKeywords = 'Access to Medicines,Medicine Prices,diabetes,Insulin'
$metaDesc = '
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions...'
$disp = '<div align="justify">-The Times of India<br /><br />This may come as a shocker. Newer and more expensive categories of insulin are being aggressively &quot;pushed&quot; by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.<br /><br />These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. <br /><br />The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.<br /><br />Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: &quot;I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations.&quot;<br /><br />In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.<br /><br />The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.<br /><br />As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee

-The Times of India This may come as a shocker. Newer and more expensive categories of insulin are being aggressively "pushed" by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime. These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients. The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors. Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: "I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations." In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150. The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say. As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.